Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Assess Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients With Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

NCT04915729 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04915729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04915729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Assess Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients With Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
June 22, 2021
Completion date
October 8, 2023
Enrollment
1,489 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

stroke